Data Sheet 3_Sustained complete response to TMEp-CI-M platform in refractory small-cell lu

A single-case report from figshare details a 60-year-old male patient with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis. The patient was treated with the TMEp-CI-M platform, achieving no evidence of disease for over 20 months. The report, authored by Yating Wu and last updated in June 2026, is shared under a CC-BY-4.0 license.

Use Cases

• Analyze the efficacy of the TMEp-CI-M platform based on the detailed treatment regimen and patient outcome described.
• Study biomarker response in immunotherapy based on the reported normalization of ProGRP levels from 1803 pg/mL to 23.71 pg/mL.
• Investigate adverse event profiles for combined immunotherapy regimens based on the reported Grade 1 hypothyroidism.
• Review a clinical case of brainstem metastasis in SCLC based on the patient history and imaging context implied in the report.

Strengths

• Provides a detailed longitudinal case report with over 20 months of follow-up data.
• Includes specific biomarker measurements (ProGRP level of 1803 pg/mL decreasing to 23.71 pg/mL).
• Describes a novel, multi-component treatment platform (TMEp-CI-M) with sequential phases.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect single-case bias inherent to a case report format.

Provenance

Source

Yating Wu

Collection Method

Clinical case report.

Freshness

Last updated 2026-06-01 05:18:39; freshness should be verified.